Description: Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.
Home Page: www.innate-pharma.com
117, Avenue de Luminy
Marseille,
13009
France
Phone:
33 4 30 30 30 30
Officers
| Name | Title |
|---|---|
| Dr. Mondher Mahjoubi M.D. | Chairman of Exec. Board & CEO |
| Mr. Yannis Morel Ph.D. | Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board |
| Dr. Herve Brailly | Co-Founder & Chairman of Supervisory Board |
| Dr. François Romagné Ph.D. | Founder |
| Mr. Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Sr. VP & Chief Scientific Officer |
| Dr. Marc Bonneville Ph.D. | Founder |
| Mr. Jean Jacques Fournié Ph.D. | Founder |
| Mr. Alessandro Moretta M.D., Ph.D. | Founder |
| Mr. Frederic Lombard M.B.A. | Sr. VP & CFO |
| Ms. Odile Belzunce | VP of Compliance & Operations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4757 |
| Price-to-Sales TTM: | 3.2659 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 213 |